Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Friday.

Other equities research analysts have also recently issued research reports about the company. Jefferies Group LLC set a $21.00 price target on Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, April 20th. Piper Jaffray Companies set a $20.00 price target on Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, July 29th. BMO Capital Markets reaffirmed a “hold” rating and issued a $16.00 price target on shares of Amphastar Pharmaceuticals in a report on Monday, July 31st. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Finally, TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, June 26th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $20.00.

Amphastar Pharmaceuticals (NASDAQ AMPH) traded down 2.4453% during trading on Friday, reaching $14.8966. The company’s stock had a trading volume of 76,607 shares. Amphastar Pharmaceuticals has a one year low of $12.05 and a one year high of $21.75. The firm has a market capitalization of $683.90 million, a P/E ratio of 193.4623 and a beta of 1.65. The stock has a 50-day moving average of $17.33 and a 200 day moving average of $15.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.06 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.43% and a net margin of 1.61%. The firm had revenue of $65.20 million during the quarter, compared to analysts’ expectations of $63.40 million. During the same quarter last year, the firm earned $0.23 earnings per share. The business’s revenue for the quarter was down 4.1% on a year-over-year basis. On average, equities research analysts predict that Amphastar Pharmaceuticals will post $0.40 EPS for the current fiscal year.

Amphastar Pharmaceuticals declared that its Board of Directors has authorized a stock repurchase program on Wednesday, August 9th that allows the company to repurchase $20.00 million in shares. This repurchase authorization allows the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/11/amphastar-pharmaceuticals-inc-amph-stock-rating-lowered-by-bidaskclub.html.

In related news, Director Richard K. Prins sold 10,000 shares of the stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $17.07, for a total value of $170,700.00. Following the completion of the transaction, the director now directly owns 28,844 shares in the company, valued at $492,367.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jason B. Shandell sold 11,482 shares of the stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $16.92, for a total value of $194,275.44. Following the completion of the transaction, the director now owns 241,342 shares of the company’s stock, valued at $4,083,506.64. The disclosure for this sale can be found here. Insiders sold 36,482 shares of company stock valued at $620,125 over the last quarter. 11.10% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of AMPH. Alps Advisors Inc. raised its position in shares of Amphastar Pharmaceuticals by 0.3% in the second quarter. Alps Advisors Inc. now owns 39,250 shares of the company’s stock valued at $701,000 after buying an additional 101 shares during the last quarter. Louisiana State Employees Retirement System raised its position in shares of Amphastar Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the company’s stock valued at $212,000 after buying an additional 200 shares during the last quarter. Arizona State Retirement System raised its position in shares of Amphastar Pharmaceuticals by 1.1% in the first quarter. Arizona State Retirement System now owns 18,700 shares of the company’s stock valued at $271,000 after buying an additional 200 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in shares of Amphastar Pharmaceuticals by 2.8% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the company’s stock valued at $151,000 after buying an additional 230 shares during the last quarter. Finally, Mason Street Advisors LLC raised its position in shares of Amphastar Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 8,394 shares of the company’s stock valued at $122,000 after buying an additional 549 shares during the last quarter. Institutional investors own 44.02% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.